北京16項輔助生殖技術項目納入醫保報銷 錦欣生殖(01951.HK)貝康醫療(02170.HK)齊漲一成
北京市醫保局會同市衛生健康委、市人力社保局印發《關於規範調整部分醫療服務價格項目的通知》,對63項醫療服務價格項目進行規範調整,並明確基本醫療保險報銷政策。其中對體外受精胚胎培養等53項輔助生殖技術項目進行了統一定價,基本涵蓋了北京市公立醫療機構開展輔助生殖的常用技術。
在規範調整63項醫療服務項目價格的同時,市醫保局、市人力社保局同步配套醫保及工傷報銷政策。其中,為實施積極生育支持措施,將門診治療中常見的宮腔內人工授精術、胚胎移植術、精子優選處理等16項涉及人群廣、診療必需、技術成熟、安全可靠的輔助生殖技術項目納入醫保甲類報銷範圍。
新政策將於3月26日落地,適用於北京市公立醫療機構,非公立醫保定點醫療機構參照執行。
受政策帶動。錦欣生殖(01951.HK)逆市造好,現升9.5%,報8.87元。截至目前,成交量約3,280萬股。貝康醫療(02170.HK)高見6.93元,最新報6.8元,升9.3%,成交45.3萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.